Pharmaron's Shaoxing Unit Passes US FDA On-Site Inspection
MT Newswires Live
Sep 16
Pharmaron Beijing's (HKG:3759, SHE:300759) wholly owned unit, Pharmaron Shaoxing Pharmaceutical, has passed a pre-approval inspection by the US Food and Drug Administration, confirming compliance with current good manufacturing practices, a Monday Hong Kong bourse filing said.
The inspection, conducted between May 29 and June 4, covered multiple GMP systems, including quality, production, equipment, packaging, and laboratory controls.
Shares of the firm were down over 1% in Tuesday morning trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.